Ullah Goraya Mohsan, Li Rui, Gu Liming, Deng Huixiong, Wang Gefei
Guangdong Provincial Key Laboratory of Infectious Diseases and Molecular Immunopathology, Shantou University Medical College, Shantou 515041, China.
Microorganisms. 2023 Mar 17;11(3):777. doi: 10.3390/microorganisms11030777.
Scientists have recently discovered a link between the circulating microbiome and homeostasis, as well as the pathogenesis of a number of metabolic diseases. It has been demonstrated that low-grade chronic inflammation is one of the primary mechanisms that has long been implicated in the risk of cardio-metabolic disease (CMDs) and its progression. Currently, the dysbiosis of circulating bacteria is considered as a key regulator for chronic inflammation in CMDs, which is why we have conducted this systemic review focused on circulating bacterial dysbiosis.
A systemic review of clinical and research-based studies was conducted via PubMed, Scopus, Medline, and Web of Science. Literature was considered for risk of bias and patterns of intervention effects. A randomized effect model was used to evaluate the dysbiosis of circulating microbiota and clinical outcomes. We conducted a meta-analysis considering the circulating bacteria in both healthy people and people with cardio-metabolic disorders, in reports published mainly from 2008 to 2022, according to the PRISMA guidelines.
We searched 627 studies and, after completing the risk of bias and selection, 31 studies comprising of 11,132 human samples were considered. This meta-analysis found that dysbiosis of phyla Proteobacteria, Firmicutes, and Bacteroidetes was associated with metabolic diseases.
In most instances, metabolic diseases are linked to higher diversity and elevated bacterial DNA levels. Bacteroides abundance was higher in healthy people than with metabolic disorders. However, more rigorous studies are required to determine the role of bacterial dysbiosis in cardio-metabolic diseases. Understanding the relationship between dysbiosis and cardio-metabolic diseases, we can use the bacteria as therapeutics for the reversal of dysbiosis and targets for therapeutics use in cardio-metabolic diseases. In the future, circulating bacterial signatures can be used as biomarkers for the early detection of metabolic diseases.
科学家们最近发现了循环微生物群与体内平衡以及多种代谢性疾病发病机制之间的联系。已有研究表明，低度慢性炎症是长期以来与心血管代谢疾病（CMD）风险及其进展相关的主要机制之一。目前，循环细菌的生态失调被认为是CMD中慢性炎症的关键调节因素，这就是我们开展这项聚焦于循环细菌生态失调的系统评价的原因。
通过PubMed、Scopus、Medline和科学网对基于临床和研究的研究进行系统评价。对文献的偏倚风险和干预效果模式进行了评估。采用随机效应模型评估循环微生物群的生态失调和临床结局。根据PRISMA指南，我们对2008年至2022年发表的报告中健康人和患有心血管代谢疾病的人的循环细菌进行了荟萃分析。
我们检索了627项研究，在完成偏倚风险评估和筛选后，纳入了31项研究，共11132份人类样本。这项荟萃分析发现，变形菌门、厚壁菌门和拟杆菌门的生态失调与代谢性疾病有关。
在大多数情况下，代谢性疾病与更高的多样性和细菌DNA水平升高有关。健康人的拟杆菌丰度高于患有代谢性疾病的人。然而，需要更严格的研究来确定细菌生态失调在心血管代谢疾病中的作用。了解生态失调与心血管代谢疾病之间的关系后，我们可以将细菌用作治疗生态失调的药物以及心血管代谢疾病治疗的靶点。未来，循环细菌特征可作为代谢性疾病早期检测的生物标志物。
